OBJECTIVE: To determine whether patients bathed daily with chlorhexidine gluconate (CHG) have a lower incidence of primary bloodstream infections (BSIs) compared with patients bathed with soap and water. METHODS: The study design was a 52-week, 2-arm, crossover (ie, concurrent control group) clinical trial with intention-to-treat analysis. The study setting was the 22-bed medical intensive care unit (MICU), which comprises 2 geographically separate, similar 11-bed units, of the John H. Stroger Jr (Cook County) Hospital, a 464-bed public teaching hospital in Chicago, Illinois. The study population comprised 836 MICU patients. During the first of 2 study periods (28 weeks), 1 hospital unit was randomly selected to serve as the intervention unit in which patients were bathed daily with 2% CHG-impregnated washcloths (Sage 2% CHG cloths; Sage Products Inc, Cary, Illinois); patients in the concurrent control unit were bathed daily with soap and water. After a 2-week wash-out period at the end of the first period, cleansing methods were crossed over for 24 more weeks. Main outcome measures included incidences of primary BSIs and clinical (culture-negative) sepsis (primary outcomes) and incidences of other infections (secondary outcomes). RESULTS: Patients in the CHG intervention arm were significantly less likely to acquire a primary BSI (4.1 vs 10.4 infections per 1000 patient days; incidence difference, 6.3 [95% confidence interval, 1.2-11.0). The incidences of other infections, including clinical sepsis, were similar between the units. Protection against primary BSI by CHG cleansing was apparent after 5 or more days in the MICU. CONCLUSION: Daily cleansing of MICU patients with CHG-impregnated cloths is a simple, effective strategy to decrease the rate of primary BSIs.
RCT Entities:
OBJECTIVE: To determine whether patients bathed daily with chlorhexidine gluconate (CHG) have a lower incidence of primary bloodstream infections (BSIs) compared with patients bathed with soap and water. METHODS: The study design was a 52-week, 2-arm, crossover (ie, concurrent control group) clinical trial with intention-to-treat analysis. The study setting was the 22-bed medical intensive care unit (MICU), which comprises 2 geographically separate, similar 11-bed units, of the John H. Stroger Jr (Cook County) Hospital, a 464-bed public teaching hospital in Chicago, Illinois. The study population comprised 836 MICU patients. During the first of 2 study periods (28 weeks), 1 hospital unit was randomly selected to serve as the intervention unit in which patients were bathed daily with 2% CHG-impregnated washcloths (Sage 2% CHG cloths; Sage Products Inc, Cary, Illinois); patients in the concurrent control unit were bathed daily with soap and water. After a 2-week wash-out period at the end of the first period, cleansing methods were crossed over for 24 more weeks. Main outcome measures included incidences of primary BSIs and clinical (culture-negative) sepsis (primary outcomes) and incidences of other infections (secondary outcomes). RESULTS:Patients in the CHG intervention arm were significantly less likely to acquire a primary BSI (4.1 vs 10.4 infections per 1000 patient days; incidence difference, 6.3 [95% confidence interval, 1.2-11.0). The incidences of other infections, including clinical sepsis, were similar between the units. Protection against primary BSI by CHG cleansing was apparent after 5 or more days in the MICU. CONCLUSION: Daily cleansing of MICU patients with CHG-impregnated cloths is a simple, effective strategy to decrease the rate of primary BSIs.
Authors: Nisha Nair; Ekaterina Kourbatova; Katharine Poole; Charmaine M Huckabee; Patrick Murray; W Charles Huskins; Henry M Blumberg Journal: Infect Control Hosp Epidemiol Date: 2011-09-20 Impact factor: 3.254
Authors: Bala Hota; Michael Lin; Joshua A Doherty; Tara Borlawsky; Keith Woeltje; Kurt Stevenson; Yosef Khan; Jeremy Young; Robert A Weinstein; William Trick Journal: J Am Med Inform Assoc Date: 2010 Jan-Feb Impact factor: 4.497
Authors: Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint Journal: Clin Infect Dis Date: 2011-05 Impact factor: 9.079
Authors: Michael W Climo; Deborah S Yokoe; David K Warren; Trish M Perl; Maureen Bolon; Loreen A Herwaldt; Robert A Weinstein; Kent A Sepkowitz; John A Jernigan; Kakotan Sanogo; Edward S Wong Journal: N Engl J Med Date: 2013-02-07 Impact factor: 91.245
Authors: Melissa A Viray; James C Morley; Craig M Coopersmith; Marin H Kollef; Victoria J Fraser; David K Warren Journal: Infect Control Hosp Epidemiol Date: 2014-01-24 Impact factor: 3.254
Authors: Arianna Miles-Jay; Susan Butler-Wu; Ali Rowhani-Rahbar; Steven A Pergam Journal: Biol Blood Marrow Transplant Date: 2014-12-11 Impact factor: 5.742